• **Name:** **Shigehisa Kitano**

• **Current Position & Affiliation:** **Director, Division of Cancer Immunotherapy Development
Center for Advanced Medical Development
The Cancer Institute Hospital of JFCR**

• **Country:** **Japan**

• Educational Background:

1998 M.D. Mie University School of Medicine, Tsu, Mie, Japan
2007 Ph.D Graduate School of Medicine, Mie University, Tsu, Mie, Japan

• Professional Experience:

2005-2007 Assistant professor, Department of Immuno-Gene Therapy
Mie University Graduate School of Medicine
2008-2009 Assistant professor, Department of Hematology and Oncology
Mie University Hospital, Tsu, Mie, Japan
2009-2013 Visiting Investigator, Ludwig Center for Cancer Immunotherapy
Memorial Sloan-Kettering Cancer Center, NYC, NY, USA
2013-2019 Stuff physician, Department of Experimental Therapeutics (phase I clinical trial)
National Cancer Center Hospital, Tsukiji, Tokyo, Japan
2019 - Director, Division of Cancer Immunology Development
Center for Advanced Medical Development
The Cancer Institute Hospital of JFCR, Ariake, Tokyo, Japan

• Professional Organizations:

American Society of Clinical Oncology (ASCO)
American Association of Cancer Research (AACR)
Japanese Association of Internal Medicine
Japanese Society of Medical Oncology (JMSO)
Japanese Society of Clinical Oncology (JSCO)
Japanese Cancer Association (JCA)
Japanese Society of Immunology (JSI)
Japanese Association of Cancer Immunology (JACI), etc.

• Main Scientific Publications:

KSMO 2020 Secretariat: P&M, 3F, MS B/D, 12, Eonju-ro 79-gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX: +82-2-557-8428 E-mail: info@ksmoconference.org

1. Kagamu H, **Kitano S**, et al. CD4^{+}T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. **Cancer Immunol Res.** 2020, 8(3), 334-344.
2. Sato J, **Kitano S**, Motoi N, Ino Y, Yamamoto N, Watanabe S, et al. CD20(+) tumor-infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma. **Cancer Sci.** 2020.
3. Hatogai K, Fujii S, **Kitano S**, Kojima T, Daiko H, Yoshino T, et al. Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma. **Br J Cancer. 2020**;122(3):413-20.
4. **Kitano S**, Nakayama T, Yamashita M. Biomarkers for Immune Checkpoint Inhibitors in Melanoma. **Front Oncol.** 2018; 8:270.
5. Tomuleasa, C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, **Kitano S**. "Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia." **Front Immunol.** 2018;9:239.
6. Tada K, **Kitano S**, Shoji H, Nishimura T, Shimada Y, Nagashima K, et al. Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. **Cancer Immunol Res.** 2016;4(7):592-9.
7. Yamashita M*, **Kitano S***, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. **Sci Rep.** 2016;6:19772. *These two auhors contributed equally.
8. **Kitano S**, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. **Cancer Immunol Res.** 2014;2(8):812-21.
9. **Kitano S**, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. **Cancer Immunol Res.** 2013;1(4):235-44.
10. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, **Kitano S**, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. **N Engl J Med.** 2012;366(10):925-31.
11. Lesokhin AM, Hohl TM, **Kitano S**, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. **Cancer Res.** 2012;72(4):876-86.
12. Hirschhorn-Cymerman D, Budhu S, **Kitano S**, Liu C, Zhao F, Zhong H, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. **J Exp Med.** 2012;209(11):2113-26.

KSMO 2020 Secretariat: P&M, 3F, MS B/D, 12, Eonju-ro 79-gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX: +82-2-557-8428 E-mail: info@ksmoconference.org